UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant \boxtimes

Filed by a Party other than the Registrant $\ \square$

Check the appropriate box:

- Preliminary Proxy Statement
- □ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- □ Soliciting Material under § 240.14a-12

PYXIS ONCOLOGY, INC.

(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- ⊠ No fee required.
- □ Fee paid previously with preliminary materials.
- □ Fee computed on table in exhibit required per Exchange Act Rules 14a-6(i)(1) and 0-11.



Pyxis Oncology, Inc. Important Notice Regarding the Availability of Proxy Materials

Stockholders Meeting to be held on June 13, 2022


For stockholders of record as of April 20, 2022

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the proxy materials, and to obtain directions to attend the meeting, go to: www.proxydocs.com/PYXS

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.



please visit www.proxydocs.com/PYXS for more details

You must register to attend the meeting online and/or participate at www.proxydocs.com/PYXS

SEE REVERSE FOR FULL AGENDA

Pyxis Oncology, Inc. Annual Meeting of Stockholders

THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

FOR ON PROPOSALS 1 AND 2

PROPOSAL

- 1. Election of Class I Director 1.01 Darren Cline
- 2. Ratification of the Appointment of Ernst & Young LLP as our Independent Registered Public Accounting Firm for the Fiscal Year ending December 31, 2022

NOTE: The transaction of such other business as may properly come before the meeting, or any adjournment or postponement thereof.